Tangier disease gene therapy - CV Therapeutics
Latest Information Update: 16 Jul 2002
At a glance
- Originator CV Therapeutics
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Tangier disease
Most Recent Events
- 29 Aug 2000 Preclinical development for Tangier disease in USA (Unknown route)
- 29 Aug 2000 New profile